Advertisement
Table 2 Split of drug costs into pre- and post-progression periods, per patient
| Pre-progression index drugs | Pre-progression concomitant drugs | Post-progression index drugs | Post-progression subsequent melanoma drugs | Post-progression concomitant drugs | Pre-progression drug costs | Post-progression drug costs | Total drug costs | |
|---|---|---|---|---|---|---|---|---|
| UK analysis | ||||||||
| NIVO + IPI (n = 177) | £135,584 | £4994 | £17,021 | £54,096 | £3262 | £140,578 | £74,379 | £214,957 |
| IPI (n = 167) | £66,115 | £1081 | £4413 | £145,037 | £4032 | £67,196 | £153,482 | £220,678 |
| NIVO (n = 170) | £109,653 | £1621 | £25,936 | £99,448 | £2843 | £111,274 | £128,266 | £239,540 |
| Difference (NIVO + IPI vs. IPI | 105% | 362% | 286% | − 63% | − 19% | 109% | − 52% | − 3% |
| Difference (NIVO + IPI vs. NIVO) | 24% | 208% | − 34% | − 46% | 15% | 26% | − 42% | − 10% |
| Germany analysis | ||||||||
| NIVO + IPI (n = 177) | €133,743 | €10,621 | €17,106 | €52,940 | €8897 | €144,364 | €78,943 | €223,307 |
| IPI (n = 167) | €63,773 | €2646 | €4250 | €152,395 | €9865 | €66,419 | €166,510 | €232,929 |
| NIVO (n = 170) | €110,977 | €5901 | €26,235 | €97,889 | €7749 | €116,878 | €131,873 | €248,751 |
| Difference (NIVO + IPI vs. IPI | 110% | 301% | 302% | − 65% | − 10% | 117% | − 53% | − 4% |
| Difference (NIVO + IPI vs. NIVO) | 21% | 80% | − 35% | − 46% | 15% | 24% | − 40% | − 10% |
